-
Sputnik V soft launched in over 50 cities
The soft launch rollout of Sputnik V has scaled up speedily and reached cities and towns all over India.
-
Dr. Reddy’s Laboratories announces commercial launch of 2-deoxy-D-glucose
2DG reduces a patient's average recovery time by two and a half days and oxygen demand by up to 40%.
-
DRDO invites EoI to transfer technology of 2-DG drug for bulk production
A higher proportion of patients treated with 2-DG have shown RT-PCR negative conversion in COVID patients.
-
Neelkanth Mishra suggests these changes for your portfolio
Credit Suisse removed Tata Steel from its 30-stock portfolio and added Hindalco citing an aluminium-to-steel price ratio near a two-decade low, an inv
-
Dr Reddy’s Laboratories announces launch of Sputnik V vaccine in India; check price details here
The soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on May 14
-
Stocks to watch: Infosys, Dr. Reddy’s Laboratories, Godrej Consumer Products, Siemens, Linde India, Kalpataru Power Transmission
Trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty could fall 29 points at the opening bell. On the macro data
-
Sputnik V Covid-19 vaccine: Dr Reddy’s expects first lot by May-end
Once available, Sputnik V will be the third vaccine to be used in India against coronavirus
-
Sputnik V: Russian Direct Investment Fund says India to produce over 850 million doses
Sputnik V will be the third vaccine to be used in India
-
COVID-19 vaccine: Biological E, Dr Reddy’s and Bharat Bio launch Phase-3 trials
After the Phase 3 data is submitted, India can expect an increase in the current rate of the immunisation programme.
